166 related articles for article (PubMed ID: 38612419)
1. The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
Di Muro G; Catalano R; Treppiedi D; Barbieri AM; Mangili F; Marra G; Di Bari S; Esposito E; Nozza E; Lania AG; Ferrante E; Locatelli M; Modena D; Steinkuhler C; Peverelli E; Mantovani G
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612419
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas.
Modena D; Moras ML; Sandrone G; Stevenazzi A; Vergani B; Dasgupta P; Kliever A; Gulde S; Marangelo A; Schillmaier M; Luque RM; Bäuerle S; Pellegata NS; Schulz S; Steinkühler C
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444563
[TBL] [Abstract][Full Text] [Related]
3. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
[TBL] [Abstract][Full Text] [Related]
4. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
Gil J; Marques-Pamies M; Valassi E; Serra G; Salinas I; Xifra G; Casano-Sancho P; Carrato C; Biagetti B; Sesmilo G; Marcos-Ruiz J; Rodriguez-Lloveras H; Rueda-Pujol A; Aulinas A; Blanco A; Hostalot C; Simó-Servat A; Muñoz F; Rico M; Ibáñez-Domínguez J; Cordero E; Webb SM; Jordà M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1129213. PubMed ID: 37033229
[TBL] [Abstract][Full Text] [Related]
6. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
[TBL] [Abstract][Full Text] [Related]
8. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
[TBL] [Abstract][Full Text] [Related]
9. A Somatostatin Receptor Subtype-3 (SST
Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
[TBL] [Abstract][Full Text] [Related]
10. A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells.
Di Muro G; Mangili F; Esposito E; Barbieri AM; Catalano R; Treppiedi D; Marra G; Nozza E; Lania AGA; Ferrante E; Locatelli M; Arosio M; Peverelli E; Mantovani G
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370829
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
Gatto F; Barbieri F; Castelletti L; Arvigo M; Pattarozzi A; Annunziata F; Saveanu A; Minuto F; Castellan L; Zona G; Florio T; Ferone D
Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
[TBL] [Abstract][Full Text] [Related]
12. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.
Lee M; Lupp A; Mendoza N; Martin N; Beschorner R; Honegger J; Schlegel J; Shively T; Pulz E; Schulz S; Roncaroli F; Pellegata NS
Endocr Relat Cancer; 2015 Feb; 22(1):111-9. PubMed ID: 25515731
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
14. Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?
Martínez-López S; García-Martínez A; Torregrosa-Quesada ME; López-Muñoz B; Cámara R; Fajardo C; Lamas C; Picó A
J Endocrinol Invest; 2020 Jun; 43(6):859-863. PubMed ID: 31898311
[TBL] [Abstract][Full Text] [Related]
15. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
16. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.
Vázquez-Borrego MC; L-López F; Gálvez-Moreno MA; Fuentes-Fayos AC; Venegas-Moreno E; Herrera-Martínez AD; Blanco-Acevedo C; Solivera J; Landsman T; Gahete MD; Soto-Moreno A; Culler MD; Castaño JP; Luque RM
Neuroendocrinology; 2020; 110(1-2):70-82. PubMed ID: 31272096
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
19. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
Yoshihara A; Isozaki O; Hizuka N; Nozoe Y; Harada C; Ono M; Kawamata T; Kubo O; Hori T; Takano K
Endocr J; 2007 Feb; 54(1):133-8. PubMed ID: 17159301
[TBL] [Abstract][Full Text] [Related]
20. Selective Interactions of Mouse Melanocortin Receptor Accessory Proteins with Somatostatin Receptors.
Wang M; Xu J; Lei XW; Zhang C; Liu SY; Jin LN; Zhang C
Cells; 2022 Jan; 11(2):. PubMed ID: 35053382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
